Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gottlieb

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|November 10, 2020
Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphomaForat Lutfi, Noa Holtzman, Jonathan Siglin, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2020
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient RegistryYadanar Lwin, Glenn Kennedy, David Gottlieb, et al.
Internal Medicine Journal|March 6, 2023
Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysisRichard Blennerhassett, Jad Othman, Amber Biscoe, et al.
Nature Communications|November 27, 2023
CAR<sup>+</sup> and CAR<sup>-</sup> T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesRaymond Hall Yip Louie, Curtis Cai, Jerome Samir, et al.
Transplantation and Cellular Therapy|May 4, 2026
Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCTStella M Davies, Emily Blyth, Catherine M Bollard, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Transplantation and Cellular Therapy|September 27, 2021
Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 PandemicDuncan Purtill, Cheryl Hutchins, Glen Kennedy, et al.
Internal Medicine Journal|June 16, 2020
Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statementNada Hamad, David Gottlieb, David Ritchie, et al.
Internal Medicine Journal|May 3, 2025
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern eraLuani Barge, Steven Tran, Glen Kennedy, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|November 10, 2020
Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphomaForat Lutfi, Noa Holtzman, Jonathan Siglin, et al.
Blood|July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-upJudith Trotman, Stephen Opat, David Gottlieb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2020
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient RegistryYadanar Lwin, Glenn Kennedy, David Gottlieb, et al.
Internal Medicine Journal|March 6, 2023
Long-term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic haemopoietic stem cell transplant: a comparative cohort analysisRichard Blennerhassett, Jad Othman, Amber Biscoe, et al.
Nature Communications|November 27, 2023
CAR<sup>+</sup> and CAR<sup>-</sup> T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesRaymond Hall Yip Louie, Curtis Cai, Jerome Samir, et al.
Transplantation and Cellular Therapy|May 4, 2026
Third-Party Viral Specific T cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCTStella M Davies, Emily Blyth, Catherine M Bollard, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Transplantation and Cellular Therapy|September 27, 2021
Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 PandemicDuncan Purtill, Cheryl Hutchins, Glen Kennedy, et al.
Internal Medicine Journal|June 16, 2020
Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statementNada Hamad, David Gottlieb, David Ritchie, et al.
Internal Medicine Journal|May 3, 2025
Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern eraLuani Barge, Steven Tran, Glen Kennedy, et al.
Pageof 9